MR Dynamic Susceptibility Contrast (DSC) perfusion imaging. Automated generation of quantitative perfusion parameter maps, without the need of manual drawing of reference tissue normalization ROIs. DSC perfusion MRI is used for assessment of tumors before, during, and after therapy to distinguish between tumor regrowth and normal treatment effects.
Product specifications Information source: Vendor
Last updated: July 29, 2020
General
Product name IB Neuro
Company Imaging Biometrics
Subspeciality Neuro
Modality CT, MR
Disease targeted Brain tumors, stroke
Key-features Automated quantification of DSC perfusion parameters
Suggested use
Data characteristics
Population All MR and CT neuro perfusion exams
Input GRE-EPI
Input format DICOM
Output RGB, monochrome (quantitative), fused overlays, automated AIF information, and reporting of DSC parameter maps
Output format Quantitative DICOM
Technology
Integration Integration in standard reading environment (PACS), Integration via AI marketplace or distribution platform, Stand-alone third party application, Plugin application to OsiriX environments
Deployment Locally on dedicated hardware, Locally virtualized (virtual machine, docker), Cloud-based, Hybrid solution
Trigger for analysis Automatically, right after the image acquisition, On demand, triggered by a user through e.g. a button click, image upload, etc.
Processing time 3 - 10 seconds
Certification
CE Certified, Class I
FDA 510(k) cleared, Class II
Market presence
On market since 2008
Distribution channels Imaging Biometrics, Eureka Clinical AI, QMENTA, Blackford Analysis, Medimsight, CorTechs Labs, Arterys
Countries present (clinical, non-research use)
Paying clinical customers (institutes)
Research/test users (institutes)
Pricing
Pricing model Pay-per-use, Subscription, Traditional License Model (purchase plus annual maintenance)
Based on Number of installations, Number of analyses
Evidence
Peer reviewed papers on performance

  • Standardization of relative cerebral blood volume (rCBV) image maps for ease of both inter- and intrapatient comparisons (read)

  • Comparison of dynamic susceptibility-weighted contrast-enhanced MR methods: recommendations for measuring relative cerebral blood volume in brain tumors (read)

  • Dynamic-susceptibility contrast agent MRI measures of relative cerebral blood volume predict response to bevacizumab in recurrent high-grade glioma (read)

  • Longitudinal DSC-MRI for Distinguishing Tumor Recurrence From Pseudoprogression in Patients With a High-grade Glioma (read)

  • Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trial (read)

  • Impact of software modeling on the accuracy of perfusion MRI in glioma (read)

  • Spatial Discrimination of Glioblastoma And Treatment Effect With Histologically-Validated Perfusion And Diffusion Magnetic Resonance Imaging Metrics (read)

  • Quantitative Delta T1 (dT1) as a Replacement for Adjudicated Central Reader Analysis of Contrast-Enhancing Tumor Burden: A Subanalysis of the American College of Radiology Imaging Network 6677/Radiation Therapy Oncology Group 0625 Multicenter Brain Tumor Trial (read)

  • Impact of software modeling on the accuracy of perfusion MRI in glioma (read)

  • Performance of Standardized Relative CBV for Quantifying Regional Histologic Tumor Burden in Recurrent High-Grade Glioma: Comparison against Normalized Relative CBV Using Image-Localized Stereotactic Biopsies (read)

Non-peer reviewed papers on performance
Other relevant papers

  • Consensus recommendations for a dynamic susceptibility contrast MRI protocol for use in high-grade gliomas Neuro-Oncology (read)

  • Repeatability of Standardized and Normalized Relative CBV in Patients with Newly Diagnosed Glioblastoma (read)

  • Moving Toward a Consensus DSC-MRI Protocol: Validation of a Low Flip Angle Single Dose Option as a Reference Standard for Brain Tumors (read)